Author:
Dzhambetova P. M.,Bisultanova Z. I.,Acaeva M. M.
Abstract
Purpose: to identify the role of the polymorphic variant of the CYP2D6*4 gene, as the most common variant among Europeans, in the diagnosis of breast cancer among 240 patients diagnosed with breast cancer and 360 women in the control group of the Chechen population. Quantitative analysis showed that the polymorphic variant CYP2D6 * 4 detection (p=0.005) increased the risk of developing a malignant tumor (OR = 1.65 (95% CI = 1.16 - 2.34). It was shown that in intermediate metabolizers, an ineffective allele breast *4 of the CYP2D6 gene can be a predictor of the development of breast cancer.
Publisher
Kemerovo State University
Reference7 articles.
1. Белушкина Н.Н. Генетические исследования мультифакториальных заболеваний в концепции персонализированной медицины. / Белушкина Н.Н., Чемезов А.С., Пальцев М.А. Профилактическая медицина. 2019. №22(3). Р.26-30., Belushkina N.N. Genetic studies of multifactorial diseases in the concept of personalized medicine. / Belushkina N.N., Chemezov A.S., Paltsev M.A. Preventive medicine. 2019. No. 22(3). R.26-30.
2. Levkovich NN. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. / Levkovich NN, Gorovenko NG, Myasoedov DV. Exp Oncol. 2011. №33(3). Р.136-139., Levkovich NN. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. / Levkovich NN, Gorovenko NG, Myasoedov DV. Exp Oncol. 2011. No. 33(3). R.136-139.
3. Mars N. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. / Mars N., Widén E., Kerminen S. et al. Nat. Commun, 2020. №11. -Р. 6383., Mars N. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. / Mars N., Widen E., Kerminen S. et al. Nat. Commun, 2020. No. 11. -R. 6383.
4. Sestak I. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. / Sestak I., Kealy R., Nikoloff M. et al. Br J Cancer, 2012. №107. Р. 230–233, Sestak I. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. / Sestak I., Kealy R., Nikoloff M. et al. Br J Cancer, 2012. No. 107. R. 230–233
5. Surekha D. CYP2D6*4 polymorphisms and breast cancer risk. / Surekha D, Sailaja K, Nageswararao D, Padma T, Raghunadharao D and Vishnupriya S. Biology and Medicine, 2010. №2 (4). Р.49-55, Surekha D. CYP2D6*4 polymorphisms and breast cancer risk. / Surekha D, Sailaja K, Nageswararao D, Padma T, Raghunadharao D and Vishnupriya S. Biology and Medicine, 2010. No. 2 (4). R.49-55